Page last updated: 2024-11-04
vorinostat and Leishmania Infection
vorinostat has been researched along with Leishmania Infection in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Patil, V | 1 |
Guerrant, W | 1 |
Chen, PC | 1 |
Gryder, B | 1 |
Benicewicz, DB | 1 |
Khan, SI | 1 |
Tekwani, BL | 1 |
Oyelere, AK | 1 |
Other Studies
1 other study available for vorinostat and Leishmania Infection
Article | Year |
---|---|
Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.
Topics: Antimalarials; Antiprotozoal Agents; Histone Deacetylase Inhibitors; Histone Deacetylases; Leishmani | 2010 |